KNOWING your patients are ready for biologic therapy

In the US, conditions treated with biologics are on the rise, including rheumatoid arthritis, plaque psoriasis, and inflammatory bowel disease.1-3

Preparing for biologic therapy: recommended screening

Administering biologic treatment causes suppression of the immune system, making those patients undergoing treatment more susceptible to infection.4

That’s why, prior to starting a patient on therapy, a number of leading health organizations, including the American College of Rheumatology (ACR) and American College of Gastroenterology (ACG), recommend screening patients for5-7:

  • Hepatitis B
  • Hepatitis C
  • TB infection
Statistics

Detect infection with the Pre-biologic Panel

Available exclusively from Quest Diagnostics, the Pre-biologic Panel includes the ACR and ACG guideline-recommended tests you need to evaluate your patients for biologic or biosimilar therapy.

Test Name

Test Components

Test Code

Pre-biologic/biosimilar Screen Panel, HCV/HBV with Reflexes and QFT 1 Tube*

Hepatitis C Antibody with Reflex to HCV RNA, PCR w/Reflex to Genotype, LiPA®

Hepatitis B Surface Antigen with Reflex Confirmation

Hepatitis B Surface Antibody Immunity, Quantitative

Hepatitis B Core Antibody, Total, with Reflex to IgM

QuantiFERON®-TB Gold Plus (1-tube option)

37616

Pre-biologic/biosimilar Screen Panel, HCV/HBV with Reflexes and QFT 4 Tubes*

Hepatitis C Antibody with Reflex to HCV RNA, PCR w/Reflex to Genotype, LiPA®

Hepatitis B Surface Antigen with Reflex Confirmation

Hepatitis B Surface Antibody Immunity, Quantitative

Hepatitis B Core Antibody, Total, with Reflex to IgM

QuantiFERON®-TB Gold Plus (4-tube option)

37620

*Panel components may be ordered separately.

Help ensure compliance and clear the way for patient therapy.

Learn more about our Pre-biologic Panel.

 

Connect with us today, and a Quest sales representative will be in touch

References

  1. Helmick CG, Felson DT, Lawrence RC, et al. Estimates of the prevalence of arthritis and other rheumatic conditions in the United States. Part I. Arthritis Rheum. 2008;58(1):15-25
  2. Crohn’s & Colitis Foundation of America. The facts about inflammatory bowel diseases. November 2014. Available here. Accessed March 8, 2019.
  3. National Psoriasis Foundation. Statistics. Available here. Accessed March 8, 2019.
  4. Kane SV. Preparing for biologic or immunosuppressant therapy. Gastroenterol Hepatol. 2011;7(8):544-546.
  5. American College of Rheumatology. 2012 Update of the 2008 American College of Rheumatology recommendations for the use of disease-modifying antirheumatic drugs and biologic agents in the treatment of rheumatoid arthritis. Arthritis Care Res. 2012;64(5):625-639.
  6. Farraye FA, Melmed GY, Lichtenstein GR, Kane SV. ACG clinical guideline: preventive care in inflammatory bowel disease. Am J Gastroenterol. 2017;112:241-258.
  7. Chebli JMF, Gaburri PD, Chebli LA, et al. A guide to preparation of patients with inflammatory bowel diseases for anti-TNF-α therapy. Med Sci Monit. 2014;20:487-498.
  8. Arthritis Foundation. Arthritis by the numbers: book of trusted facts & figures. 2018;2:8. Available here. Accessed March 14, 2019.